France picks Germany's Boehringer Ingelheim for bird flu vaccines
Send a link to a friend
[July 13, 2023] By
Sybille de La Hamaide
PARIS (Reuters) -France has chosen German company Boehringer Ingelheim
to supply the 80 million doses of bird flu vaccines needed for its
vaccination campaign to start in October, an agriculture ministry
spokesperson told Reuters on Wednesday.
The government launched a tender in April to vaccinate ducks against
avian influenza, commonly called bird flu, that has ravaged flocks
around the world and led to the culling of hundreds of millions of
birds.
The campaign would make France the first country in the European Union
to vaccinate poultry against the deadly virus.
Agriculture ministry officials said last month that tests carried out in
France on vaccines from French firm Ceva Animal Health and Boehringer
Ingelheim showed favourable results.
The ministry did not quantify the value of the order, but said
Boehringer's offer was considered better than Ceva's due to the
financial criteria, its capacity to supply the doses and storage
conditions.
Boehringer Ingelheim and Ceva declined to comment.
[to top of second column]
|
Ducks are seen in a field in Bourriot
Bergonce, southwestern France, January 7, 2017. REUTERS/Regis
Duvignau/File Photo
The French poultry industry had
asked to have two different vaccines to avoid supply hiccups. They
also preferred a vaccine with one of the two doses injected in
hatcheries, like Ceva's vaccine, making it easier for farmers,
according to a letter from several industry groups to the
agriculture ministry, seen by Reuters.
U.S. company Zoetis had also applied in the tender but its vaccine
did not cover the species of ducks that France wanted to vaccinate
initially, the ministry said.
"If the decision to vaccinate all year round is taken, a new call
for tenders should be launched for an additional order of vaccines
with a new call for tender," the spokesperson said in a written
answer.
(Reporting by Sybille de La Hamaide; Editing by Benoit Van
Overstraeten and Devika Syamnath)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |